Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”

Détails bibliographiques
Auteur principal:	Daniel Mazza Matos
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	HemaSphere
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Diagnosis without consent: A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
par: Richard J. Buka
Publié: (2026)

De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria
par: Peter Johnstone, et autres
Publié: (2025)

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
par: Thomas Chatzikonstantinou, et autres
Publié: (2024)

Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020
par: Lina van der Straten, et autres
Publié: (2024)

Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
par: Arnon P. Kater, et autres
Publié: (2024)

Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
par: Kostas Stamatopoulos, et autres
Publié: (2024)

Sharper definitions, blurred lines: The clinical aftermath of the revised antiphospholipid syndrome criteria
par: Lauren E. Merz, et autres
Publié: (2026)

The role of trephine bone marrow biopsies in the era of measurable residual disease — Results from the CLL10 trial of the German CLL Study Group (GCLLSG)
par: Nadine Kutsch, et autres
Publié: (2024)

Flow cytometry interference in patients treated with tafasitamab: Unraveling the diagnostic maze
par: Lisa Proost, et autres
Publié: (2024)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
par: Raúl Córdoba, et autres
Publié: (2026)

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real‐world patients
par: Claudia Bellofiore, et autres
Publié: (2026)

Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies
par: Eirini Katodritou, et autres
Publié: (2025)

IL21—STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemia
par: Rosita Del Prete, et autres
Publié: (2026)

Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience
par: Paolo Ghia, et autres
Publié: (2025)

Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B‐cell‐related epigenetic imprinting and genetic alterations
par: Stella Charalampopoulou, et autres
Publié: (2026)

Comparative analysis of macrophage feeder systems reveals distinct behaviors and key transcriptional shifts in chronic lymphocytic leukemia cells via coculture
par: Viktoria Kohlhas, et autres
Publié: (2025)

A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia
par: Elisa Lenti, et autres
Publié: (2025)

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
par: Gian Matteo Rigolin, et autres
Publié: (2024)

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience
par: Idanna Innocenti, et autres
Publié: (2024)

Robust and cost‐effective CRISPR/Cas9 gene editing of primary tumor B cells in Eµ‐TCL1 model of chronic lymphocytic leukemia
par: Rosita Del Prete, et autres
Publié: (2024)

3D Tumor microenvironment interaction reveals AP‐1 complex regulation and contact‐mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia
par: Jana Lindacher, et autres
Publié: (2025)

Extracellular vesicles from chronic lymphocytic leukemia cells promote leukemia aggressiveness by inducing the differentiation of monocytes into nurse‐like cells via an RNA‐dependent mechanism
par: Nathan Dubois, et autres
Publié: (2025)

Casein kinase 1δ/ε inhibition suppresses CLL proliferation through cell‐intrinsic and microenvironmental mechanisms
par: Antonia Mikulova, et autres
Publié: (2026)

Implementation science in hemato‐oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)
par: Jean‐Michel Cayuela, et autres
Publié: (2025)

Unveiling relative lymphopenia and elevated monocyte‐to‐lymphocyte count as novel independent adverse prognostic factors in chronic myelomonocytic leukemia (CMML)—Proposal of the objective prognostic index for CMML (OPIC)
par: Xavier Calvo, et autres
Publié: (2026)

NOTCH1 fusions in pediatric T‐cell lymphoblastic lymphoma: A high‐risk subgroup with CCL17 (TARC) levels as diagnostic biomarker
par: Emma Kroeze, et autres
Publié: (2024)

CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience
par: Riccardo Bomben, et autres
Publié: (2024)

First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis
par: Paolo Ghia, et autres
Publié: (2024)

Validation of the diagnostic potential of 17 immunophenotypic core markers defined by the ELN‐iMDS‐Flow Working Group in an independent cohort of patients with MDS
par: Coen R. Veenstra, et autres
Publié: (2025)

NK‐type large granular lymphocyte leukemia comes of age
par: Gianpietro Semenzato, et autres
Publié: (2025)

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL
par: Sarka Pavlova, et autres
Publié: (2025)

Obituary for a diagnosis: B‐cell prolymphocytic leukaemia (1974–2022)
par: Stephen P. Hibbs, et autres
Publié: (2024)

A RiboCancer cell line panel reveals that CLL‐associated Rps15 mutations translationally rewire transcription through codon‐specific tRNA accommodation defects
par: Anaïs Astier, et autres
Publié: (2026)

Impact of the kinetics of circulating anti‐BCMA CAR‐T cells and normal lymphocytes on the outcome of MM patients
par: Sara Gutiérrez‐Herrero, et autres
Publié: (2025)

Daratumumab‐based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case‐control study
par: Claudia Bellofiore, et autres
Publié: (2025)

Chronic lymphocytic leukemia with IGH :: BCL3 ‐translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape
par: Cosima Drewes, et autres
Publié: (2026)

HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
par: Sophie Le Grand, et autres
Publié: (2025)

Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
par: Cristina De Ramón, et autres
Publié: (2024)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
par: Ola Landgren, et autres
Publié: (2025)

Cellular therapies for sickle cell disease: Should we be calling them a cure?
par: Lydia O. Okoibhole, et autres
Publié: (2025)

Documents similaires

Documents similaires